Page 3 of 28

In the Claims

Docket No.: 74.US2.PCT

Please amend the claims according to the claim listing provided below.

#### Marked-Up Copy of Claims:

# 1. (Original) A compound of Formula I:

$$R^1$$
 $R^2$ 
 $R^2$ 

or a pharmaceutically acceptable salt, hydrate or solvate thereof, wherein:

Ar<sup>1</sup> is aryl, heteroaryl, biaryl, biheteroaryl, arylheteroaryl or heteroarylaryl, wherein Ar<sup>1</sup> is optionally substituted with one or more substituents selected from halo, cyano, nitro,  $C_{1-6}$  alkyl,  $C_{1-6}$  haloalkyl,  $C_{2-6}$  alkenyl,  $C_{2-6}$  alkynyl, carbocyclyl optionally substituted by one or more  $R^{13}$ , heterocyclyl optionally substituted by one or more  $R^{13}$ , carbocyclylalkenyl optionally substituted by one or more  $R^{13}$ , carbocyclylalkynyl optionally substituted by one or more  $R^{13}$ , heterocyclylalkyl optionally substituted by one or more  $R^{13}$ , heterocyclylalkenyl optionally substituted by one or more  $R^{13}$ , heterocyclylalkenyl optionally substituted by one or more  $R^{13}$ , heterocyclylalkenyl optionally substituted by one or more  $R^{13}$ , heterocyclylalkenyl optionally substituted by one or more  $R^{13}$ , heterocyclylalkenyl optionally substituted by one or more  $R^{13}$ , heterocyclylalkenyl optionally substituted by one or more  $R^{13}$ , hydroxylamino,  $R^{13}$ ,  $R^{13}$ , hydroxylamino,  $R^{13}$ ,  $R^$ 

Ar<sup>2</sup> is aryl or heteroaryl, each optionally substituted with one or more substituents selected from halo, cyano, nitro,  $C_{1-6}$  alkyl,  $C_{1-6}$  haloalkyl,  $C_{2-6}$  alkenyl,  $C_{2-6}$  alkynyl, carbocyclyl optionally substituted by one or more  $R^{14}$ , heterocyclyl optionally substituted by one or more  $R^{14}$ , hydroxylamino,  $OR^9$ ,  $SR^9$ ,  $SOR^{10}$ ,  $SO_2R^{10}$ ,  $COR^{10}$ ,  $COOR^9$ ,  $OC(O)R^{10}$  or  $NR^{11}R^{12}$ ;

D is N, C or CR<sup>3</sup>;

 $\underline{---}$  is a single bond when D is N or  $\mathbb{CR}^3$ ;

--- is a double bond when D is C;

 $A^1$  is absent or a  $C_{1-3}$  straight-chain aliphatic group optionally substituted with one or more substituents selected from halo,  $C_{1-4}$  alkyl,  $C_{1-4}$  haloalkyl,  $C_{1-4}$  alkoxy,  $C_{1-4}$  haloalkoxy, amino,  $(C_{1-6}$  alkyl)amino, hydroxy, carboxy,  $(C_{1-4}$  alkoxy)carbonyl, or cyano;

Page 4 of 28

 $A^2$  is  $C_{1-4}$  straight-chain aliphatic group optionally substituted with one or more substituents selected from halo,  $C_{1-4}$  alkyl,  $C_{1-4}$  haloalkyl,  $C_{1-4}$  alkoxy,  $C_{1-4}$  haloalkoxy, amino,  $(C_{1-6}$  alkyl)amino, di( $C_{1-6}$  alkyl)amino, hydroxy, carboxy,  $(C_{1-4}$  alkoxy)carbonyl, or cyano;

Docket No.: 74.US2.PCT

E is CO, C(O)O, C(O)NR<sup>4</sup>, NR<sup>4</sup>CONR<sup>4</sup>, SO, SO<sub>2</sub>, SONR<sup>4</sup>, SO<sub>2</sub>NR<sup>4</sup>, or a bond;

G is  $C_{1-3}$  alkylene,  $C_{2-3}$  alkenylene or  $C_{2-3}$  alkynylene optionally substituted with one or more substituents selected from halo,  $C_{1-4}$  alkyl,  $C_{1-4}$  haloalkyl,  $C_{1-4}$  alkoxy,  $C_{1-4}$  haloalkoxy, amino,  $(C_{1-4}$  alkyl)amino, di( $C_{1-4}$  alkyl)amino, hydroxy, carboxy,  $(C_{1-4}$  alkoxy)carbonyl, or cyano;

R<sup>1</sup> is H, C<sub>1-6</sub> alkyl, C<sub>2-6</sub> alkenyl or C<sub>2-6</sub> alkynyl, wherein R<sup>1</sup> is optionally substituted with one or more substituents selected from halo, OH, SH, nitro, cyano, C<sub>1-4</sub> haloalkyl, C<sub>1-5</sub> acyl, C<sub>1-5</sub> acyloxy, C<sub>1-4</sub> alkoxy, C<sub>1-4</sub> thioalkoxy, C<sub>1-4</sub> haloalkoxy, amino, (C<sub>1-4</sub> alkyl)amino, di(C<sub>1-4</sub> alkyl)amino, aminocarbonyl, (C<sub>1-4</sub> alkyl)aminocarbonyl, di(C<sub>1-4</sub> alkyl)aminocarbonyl, C<sub>1-4</sub> alkylsulfinyl, C<sub>1-4</sub> alkylsulfinyl, C<sub>1-4</sub> haloalkylsulfinyl, aminosulfonyl, (C<sub>1-4</sub> alkyl)aminosulfonyl, di(C<sub>1-4</sub> alkyl)aminosulfonyl, ureido, C<sub>1-4</sub> alkylureido, di(C<sub>1-4</sub> alkyl)ureido, thioureido, C<sub>1-4</sub> alkylthioureido, di(C<sub>1-4</sub> alkyl)thioureido, carboxy, (C<sub>1-6</sub> alkoxy)carbonyl, and hydroxylamino;

 $R^2$  is H,  $C_{1-6}$  alkyl,  $C_{2-6}$  alkenyl or  $C_{2-6}$  alkynyl, wherein  $R^2$  is optionally substituted with one or more substituents selected from halo, OH, SH, nitro, cyano,  $C_{1-4}$  haloalkyl,  $C_{1-5}$  acyl,  $C_{1-5}$  acyloxy,  $C_{1-4}$  alkoxy,  $C_{1-4}$  thioalkoxy,  $C_{1-4}$  haloalkoxy, amino,  $(C_{1-4}$  alkyl)amino, di $(C_{1-4}$  alkyl)amino, aminocarbonyl,  $(C_{1-4}$  alkyl)aminocarbonyl,  $(C_{1-4}$  alkyl)aminocarbonyl,  $(C_{1-4}$  alkylsulfinyl,  $(C_{1-4}$  alkylsulfinyl,  $(C_{1-4}$  alkyl)aminosulfonyl, aminosulfonyl,  $(C_{1-4}$  alkyl)aminosulfonyl, di $(C_{1-4}$  alkyl)aminosulfonyl, ureido,  $(C_{1-4}$  alkyl)ureido, thioureido,  $(C_{1-4}$  alkyl)thioureido, carboxy,  $(C_{1-6}$  alkoxy)carbonyl, and hydroxylamino;

or R<sup>1</sup> and R<sup>2</sup> together with the carbon atoms to which they are attached and the two carbon atoms through which the isoxazole and thiazole moieties of the core are joined form a fused C<sub>5-7</sub> carbocyclyl group or fused 5-7 membered heterocyclyl group optionally substituted with one or more substituents selected from halo, C<sub>1-4</sub> alkyl, C<sub>1-4</sub> haloalkyl, C<sub>1-4</sub> alkoxy, C<sub>1-4</sub> haloalkoxy, amino, (C<sub>1-4</sub> alkyl)amino, di(C<sub>1-4</sub> alkyl)amino, hydroxy, carboxy, (C<sub>1-4</sub> alkoxy)carbonyl, or cyano;

R<sup>3</sup> is H or C<sub>1-6</sub> alkyl;

R<sup>4</sup>, at each independent occurrence, is H or C<sub>1-4</sub> alkyl;

 $R^5$  and  $R^9$  are each, independently, H,  $C_{1-8}$  alkyl,  $C_{1-8}$  haloalkyl,  $C_{2-8}$  alkenyl,  $C_{2-8}$  alkynyl, aryl, heteroaryl,  $C_{3-7}$  cycloalkyl, 5-7 membered heterocycloalkyl, arylalkyl, heteroarylalkyl, ( $C_{3-7}$  cycloalkyl)alkyl or (5-7 membered heterocycloalkyl)alkyl;

Page 5 of 28

R<sup>6</sup> and R<sup>10</sup> are each, independently, H, C<sub>1-8</sub> alkyl, C<sub>1-8</sub> haloalkyl, C<sub>2-8</sub> alkenyl, C<sub>2-8</sub> alkynyl, aryl, heteroaryl, C<sub>3-7</sub> cycloalkyl, 5-7 membered heterocycloalkyl, arylalkyl, heteroarylalkyl, (C<sub>3-7</sub> cycloalkyl)alkyl, (5-7 membered heterocycloalkyl)alkyl, amino, (C<sub>1-4</sub> alkyl)amino, di(C<sub>1-4</sub> alkyl)amino,

 $R^7$  and  $R^8$  are each, independently, H,  $C_{1-8}$  alkyl,  $C_{2-8}$  alkenyl,  $C_{2-8}$  alkynyl, aryl, heteroaryl,  $C_{3-7}$  cycloalkyl, 5-7 membered heterocycloalkyl, arylalkyl, heteroarylalkyl,  $(C_{3-7}$  cycloalkyl)alkyl, (5-7 membered heterocycloalkyl)alkyl,  $(C_{1-8}$  alkyl)carbonyl,  $(C_{1-8}$  haloalkyl)carbonyl,  $(C_{1-8}$  haloalkyl)carbonyl,  $(C_{1-8}$  haloalkoxy)carbonyl,  $(C_{1-4}$  alkyl)sulfonyl,  $(C_{1-4}$  haloalkyl)sulfonyl or arylsulfonyl;

or R<sup>7</sup> and R<sup>8</sup>, together with the N atom to which they are attached form a 5-7 membered heterocycloalkyl group;

 $R^{11}$  and  $R^{12}$  are each, independently, H,  $C_{1-8}$  alkyl,  $C_{2-8}$  alkenyl,  $C_{2-8}$  alkynyl, aryl, heteroaryl,  $C_{3-7}$  cycloalkyl, 5-7 membered heterocycloalkyl, arylalkyl, heteroarylalkyl,  $(C_{3-7}$  cycloalkyl)alkyl,  $(S_{3-7}$  cycloalkyl)alkyl,  $(S_{1-8}$  alkyl)carbonyl,  $(C_{1-8}$  haloalkyl)carbonyl,  $(C_{1-8}$  haloalkyl)carbonyl,  $(C_{1-8}$  haloalkoxy)carbonyl,  $(C_{1-4}$  alkyl)sulfonyl,  $(C_{1-4}$  haloalkyl)sulfonyl or arylsulfonyl;

or R<sup>11</sup> and R<sup>12</sup>, together with the N atom to which they are attached form a 5-7 membered heterocycloalkyl group; and

 $R^{13}$  and  $R^{14}$  are each, independently, halo, cyano, nitro,  $C_{14}$  alkyl,  $C_{14}$  haloalkyl,  $C_{14}$  alkoxy,  $C_{14}$  haloalkoxy, amino,  $(C_{14}$  alkyl)amino, di $(C_{14}$  alkyl)amino, hydroxy, carboxy,  $(C_{14}$  alkoxy)carbonyl,  $C_{14}$  acyloxy, aminocarbonyl,  $(C_{14}$  alkyl)aminocarbonyl, or di $(C_{14}$  alkyl)aminocarbonyl.

2. (Original) The compound of claim 1 wherein  $Ar^1$  is aryl, heteroaryl, biaryl, biheteroaryl, arylheteroaryl or heteroarylaryl, wherein  $Ar^1$  is substituted with 1, 2 or 3 substituents selected from halo, cyano, nitro,  $C_{1-6}$  alkyl,  $C_{1-6}$  haloalkyl,  $C_{2-6}$  alkenyl,  $C_{2-6}$  alkynyl, carbocyclyl optionally substituted by one or more  $R^{13}$ , carbocyclylalkyl optionally substituted by one or more  $R^{13}$ , carbocyclylalkenyl optionally substituted by one or more  $R^{13}$ , carbocyclylalkynyl optionally substituted by one or more  $R^{13}$ , heterocyclylalkyl optionally substituted by one or more  $R^{13}$ , heterocyclylalkenyl optionally substituted by one or more  $R^{13}$ , heterocyclylalkynyl optionally substituted by one or more  $R^{13}$ , heterocyclylalkynyl optionally substituted by one or more  $R^{13}$ , heterocyclylalkynyl optionally substituted by one or more  $R^{13}$ , hydroxylamino,  $R^{13}$ , holoxylamino,  $R^{13}$ , holoxylamino, hol

Page 6 of 28

3. (Original) The compound of claim 1 wherein Ar<sup>1</sup> is aryl, heteroaryl, biaryl, biheteroaryl, arylheteroaryl or heteroarylaryl, wherein Ar<sup>1</sup> is optionally substituted with one or more substituents selected from halo, cyano, nitro, heterocyclyl optionally substituted by one or more R<sup>13</sup>, heterocyclylalkyl optionally substituted by one or more R<sup>13</sup>, heterocyclylalkenyl optionally substituted by one or more R<sup>13</sup>, heterocyclylalkynyl optionally substituted by one or more R<sup>13</sup>, hydroxylamino, OR<sup>5</sup>, SR<sup>5</sup>, SOR<sup>6</sup>, SO<sub>2</sub>R<sup>6</sup>, COR<sup>6</sup>, COOR<sup>5</sup>, OC(O)R<sup>6</sup> or NR<sup>7</sup>R<sup>8</sup>.

- 4. (Original) The compound of claim 1 wherein  $Ar^1$  is aryl, biaryl or heteroarylaryl, wherein  $Ar^1$  is optionally substituted with one or more substituents selected from halo, cyano, nitro,  $C_{1-6}$  alkyl,  $C_{1-6}$  haloalkyl,  $C_{2-6}$  alkenyl,  $C_{2-6}$  alkynyl, carbocyclyl optionally substituted by one or more  $R^{13}$ , heterocyclyl optionally substituted by one or more  $R^{13}$ , carbocyclylalkyl optionally substituted by one or more  $R^{13}$ , carbocyclylalkynyl optionally substituted by one or more  $R^{13}$ , heterocyclylalkyl optionally substituted by one or more  $R^{13}$ , heterocyclylalkenyl optionally substituted by one or more  $R^{13}$ , heterocyclylalkenyl optionally substituted by one or more  $R^{13}$ , heterocyclylalkenyl optionally substituted by one or more  $R^{13}$ , heterocyclylalkynyl optionally substituted by one or more  $R^{13}$ , hydroxylamino,  $R^{13}$ ,  $R^{13}$ ,
- 5. (Original) The compound of claim 1 wherein Ar<sup>1</sup> is phenyl, biphenyl or heteroarylphenyl, wherein Ar<sup>1</sup> is optionally substituted with one or more substituents selected from halo, cyano, nitro, C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>1</sub>-C<sub>6</sub> haloalkyl, C<sub>2</sub>-C<sub>6</sub> alkenyl, C<sub>2</sub>-C<sub>6</sub> alkynyl, carbocyclyl optionally substituted by one or more R<sup>13</sup>, heterocyclyl optionally substituted by one or more R<sup>13</sup>, carbocyclylalkyl optionally substituted by one or more R<sup>13</sup>, carbocyclylalkynyl optionally substituted by one or more R<sup>13</sup>, heterocyclylalkynyl optionally substituted by one or more R<sup>13</sup>, hydroxylamino, OR<sup>5</sup>, SR<sup>5</sup>, SOR<sup>6</sup>, SO<sub>2</sub>R<sup>6</sup>, COR<sup>6</sup>, COOR<sup>5</sup>, OC(O)R<sup>6</sup> or NR<sup>7</sup>R<sup>8</sup>.
- 6. (Original) The compound of claim 1 wherein Ar<sup>1</sup> is phenyl, biphenyl or heteroarylphenyl, wherein Ar<sup>1</sup> is optionally substituted with 1, 2 or 3 substituents selected from halo, cyano, nitro, heterocyclyl optionally substituted by one or more R<sup>13</sup>, heterocyclylalkyl optionally substituted by one or more R<sup>13</sup>, heterocyclylalkenyl optionally substituted by one or more R<sup>13</sup>, heterocyclylalkynyl optionally substituted by one or more R<sup>13</sup>, hydroxylamino, OR<sup>5</sup>, SR<sup>5</sup>, SOR<sup>6</sup>, SO<sub>2</sub>R<sup>6</sup>, COR<sup>6</sup>, COOR<sup>5</sup>, OC(O)R<sup>6</sup> or NR<sup>7</sup>R<sup>8</sup>.

Page 7 of 28

7. (Original) The compound of claim 1 wherein  $Ar^1$  is phenyl, biphenyl or heteroarylphenyl, wherein  $Ar^1$  is substituted with 1, 2 or 3 substituents selected from halo, cyano, nitro, heterocyclyl optionally substituted by one or more  $R^{13}$ , heterocyclylalkynyl optionally substituted by one or more  $R^{13}$ ,  $C_{1.4}$  alkoxy,  $SO_2R^6$ ,  $COR^6$ ,  $COOR^5$  or  $NR^7R^8$ .

Docket No.: 74.US2.PCT

- 8. (Original) The compound of claim 1 wherein  $Ar^2$  is aryl or heteroaryl, each optionally substituted with 1, 2 or 3 substituents selected from halo, cyano, nitro,  $C_{1-6}$  alkyl,  $C_{1-6}$  haloalkyl,  $C_{2-6}$  alkenyl,  $C_{2-6}$  alkynyl, carbocyclyl optionally substituted by one or more  $R^{14}$ , heterocyclyl optionally substituted by one or more  $R^{14}$ , hydroxylamino,  $OR^9$ ,  $SR^9$ ,  $SOR^{10}$ ,  $SO_2R^{10}$ ,  $COR^{10}$ ,  $COOR^9$ ,  $OC(O)R^{10}$  or  $NR^{11}R^{12}$ .
- 9. (Original) The compound of claim 1 wherein Ar<sup>2</sup> is aryl or heteroaryl.
- 10. (Original) The compound of claim 1 wherein Ar<sup>2</sup> is heteroaryl.
- 11. (Original) The compound of claim 1 wherein Ar<sup>2</sup> is thienyl.
- 12. (Original) The compound of claim 1 wherein Ar<sup>2</sup> is aryl.
- 13. (Original) The compound of claim 1 wherein Ar<sup>2</sup> is phenyl.
- 14. (Original) The compound of claim 1 wherein D is CR<sup>3</sup>.
- 15. (Original) The compound of claim 1 wherein D is CH.
- 16. (Original) The compound of claim 1 wherein  $A^1$  is a  $C_{1-3}$  alkylene group.
- 17. (Original) The compound of claim 1 wherein A<sup>1</sup> is CH<sub>2</sub> or CH<sub>2</sub>CH<sub>2</sub>.
- 18. (Original) The compound of claim 1 wherein A<sup>1</sup> is absent.
- 19. (Original) The compound of claim 1 wherein D is CR<sup>3</sup> and A<sup>2</sup> is a C<sub>1-3</sub> alkylene group.
- 20. (Original) The compound of claim 1 wherein D is CR<sup>3</sup> and A<sup>2</sup> is CH<sub>2</sub>CH<sub>2</sub> or CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>.

Page 8 of 28

21. (Original) The compound of claim 1 wherein D is CR<sup>3</sup>, A<sup>1</sup> is CH<sub>2</sub>CH<sub>2</sub>, and A<sup>2</sup> is CH<sub>2</sub>CH<sub>2</sub>.

22. (Original) The compound of claim 1 wherein D is CR<sup>3</sup>, A<sup>1</sup> is absent, and A<sup>2</sup> is CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>.

23. (Original) The compound of claim 1 wherein E is CO, C(O)O, C(O)NR<sup>4</sup>, SO<sub>2</sub> or a bond.

24. (Original) The compound of claim 1 wherein E is CO or SO<sub>2</sub>.

25. (Original) The compound of claim 1 wherein E is CO.

26. (Original) The compound of claim 1 wherein G is  $C_{1-3}$  alkylene.

27. (Original) The compound of claim 1 wherein G is CH<sub>2</sub> or CH<sub>2</sub>CH<sub>2</sub>.

28. (Original) The compound of claim 1 wherein G is CH<sub>2</sub>.

29. (Original) The compound of claim 1 wherein  $R^1$  is H or  $C_{1-4}$  alkyl.

30. (Original) The compound of claim 1 wherein R<sup>1</sup> is methyl.

#### 31. (Original) The compound of claim 1 wherein:

 $R^1$  is H,  $C_{1-6}$  alkyl,  $C_{2-6}$  alkenyl or  $C_{2-6}$  alkynyl, wherein  $R^1$  is optionally substituted with one or more substituents selected from halo, OH, SH, nitro, cyano,  $C_{1-4}$  haloalkyl,  $C_{1-5}$  acyl,  $C_{1-5}$  acyloxy,  $C_{1-4}$  alkoxy,  $C_{1-4}$  thioalkoxy,  $C_{1-4}$  haloalkoxy, amino,  $(C_{1-4}$  alkyl)amino, di( $C_{1-4}$  alkyl)amino, aminocarbonyl,  $(C_{1-4}$  alkyl)aminocarbonyl,  $(C_{1-4}$  alkyl)aminocarbonyl,  $(C_{1-4}$  alkylsulfinyl,  $C_{1-4}$  alkylsulfinyl,  $(C_{1-4}$  alkyl)aminosulfonyl, aminosulfonyl,  $(C_{1-4}$  alkyl)aminosulfonyl, di( $(C_{1-4}$  alkyl)aminosulfonyl, ureido,  $(C_{1-4}$  alkyl)ureido, thioureido,  $(C_{1-4}$  alkyl)thioureido, carboxy,  $(C_{1-6}$  alkoxy)carbonyl, and hydroxylamino; and

 $R^2$  is H,  $C_{1-6}$  alkyl,  $C_{2-6}$  alkenyl or  $C_{2-6}$  alkynyl, wherein  $R^2$  is optionally substituted with one or more substituents selected from halo, OH, SH, nitro, cyano,  $C_{1-4}$  haloalkyl,  $C_{1-5}$  acyl,  $C_{1-5}$  acyloxy,  $C_{1-4}$  alkoxy,  $C_{1-4}$  thioalkoxy,  $C_{1-4}$  haloalkoxy, amino,  $(C_{1-4}$  alkyl)amino, di( $C_{1-4}$  alkyl)amino, aminocarbonyl,  $(C_{1-4}$  alkyl)aminocarbonyl,  $(C_{1-4}$  alkyl)aminocarbonyl

Page 9 of 28

alkylsulfonyl,  $C_{14}$  haloalkylsulfinyl,  $C_{14}$  haloalkylsulfonyl, aminosulfonyl,  $(C_{14}$  alkyl)aminosulfonyl, di $(C_{14}$  alkyl)aminosulfonyl, ureido,  $C_{14}$  alkylureido, di $(C_{14}$  alkyl)ureido, thioureido,  $C_{14}$  alkylthioureido, di $(C_{14}$  alkyl)thioureido, carboxy,  $(C_{16}$  alkoxy)carbonyl, and hydroxylamino.

- 32. (Original) The compound of claim 1 wherein  $R^2$  is H or  $C_{1-4}$  alkyl.
- 33. (Original) The compound of claim 1 wherein  $R^2$  is H.
- 34. (Original) The compound of claim 1 wherein R<sup>3</sup> is H.
- 35. (Original) The compound of claim 1 wherein R<sup>4</sup>, at each independent occurrence, is H.
- 36. (Original) The compound of claim 1 wherein:

D is CR<sup>3</sup>;

 $A^1$  is a absent or a  $C_{1-3}$  alkylene group;

 $A^2$  is a  $C_{1-3}$  alkylene group;

E is CO, C(O)O, C(O)NR<sup>4</sup>, SO<sub>2</sub> or a bond;

G is C<sub>1-3</sub> alkylene;

R<sup>1</sup> is H or C<sub>1-6</sub> alkyl; and

 $R^2$  is H or  $C_{1-6}$  alkyl.

### 37. (Original) The compound of claim 1 wherein:

Ar<sup>2</sup> is aryl or heteroaryl, each optionally substituted with 1, 2 or 3 substituents selected from halo, cyano, nitro, C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>1</sub>-C<sub>6</sub> haloalkyl, C<sub>2</sub>-C<sub>6</sub> alkenyl, C<sub>2</sub>-C<sub>6</sub> alkynyl, carbocyclyl optionally substituted by one or more R<sup>14</sup>, heterocyclyl optionally substituted by one or more R<sup>14</sup>, hydroxylamino, OR<sup>9</sup>, SR<sup>9</sup>, SOR<sup>10</sup>, SO<sub>2</sub>R<sup>10</sup>, COR<sup>10</sup>, COOR<sup>9</sup>, OC(O)R<sup>10</sup> or NR<sup>11</sup>R<sup>12</sup>;

D is CR<sup>3</sup>;

A<sup>1</sup> is absent or a C<sub>1-3</sub> alkylene group;

 $A^2$  is a  $C_{1-3}$  alkylene group;

E is CO, C(O)O, C(O)NR<sup>4</sup>, SO<sub>2</sub> or a bond;

G is C<sub>1-3</sub> alkylene;

 $R^1$  is H or  $C_{1-6}$  alkyl; and

 $R^2$  is H or  $C_{1-6}$  alkyl.

Page 10 of 28

## 38. (Original) The compound of claim 1 wherein:

Ar<sup>1</sup> is phenyl, biphenyl or heteroarylphenyl, wherein Ar<sup>1</sup> is optionally substituted with one or more substituents selected from halo, cyano, nitro, C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>1</sub>-C<sub>6</sub> haloalkyl, C<sub>2</sub>-C<sub>6</sub> alkenyl, C<sub>2</sub>-C<sub>6</sub> alkynyl, carbocyclyl optionally substituted by one or more R<sup>13</sup>, heterocyclyl optionally substituted by one or more R<sup>13</sup>, carbocyclylalkyl optionally substituted by one or more R<sup>13</sup>, carbocyclylalkynyl optionally substituted by one or more R<sup>13</sup>, heterocyclylalkyl optionally substituted by one or more R<sup>13</sup>, heterocyclylalkyl optionally substituted by one or more R<sup>13</sup>, heterocyclylalkyl optionally substituted by one or more R<sup>13</sup>, heterocyclylalkynyl optionally substituted by one or more R<sup>13</sup>, hydroxylamino, OR<sup>5</sup>, SR<sup>5</sup>, SOR<sup>6</sup>, SO<sub>2</sub>R<sup>6</sup>, COR<sup>6</sup>, COOR<sup>5</sup>, OC(O)R<sup>6</sup> or NR<sup>7</sup>R<sup>8</sup>;

Docket No.: 74.US2.PCT

Ar<sup>2</sup> is aryl or heteroaryl;

D is CR<sup>3</sup>;

A<sup>1</sup> is absent or a C<sub>1-3</sub> alkylene group;

 $A^2$  is a  $C_{1-3}$  alkylene group;

E is CO, C(O)O, C(O)NR<sup>4</sup>, SO<sub>2</sub> or a bond;

G is C<sub>1-3</sub> alkylene;

R<sup>1</sup> is H or C<sub>1-6</sub> alkyl; and

 $R^2$  is H or  $C_{1-6}$  alkyl.

#### 39. (Original) The compound of claim 1 wherein:

Ar<sup>1</sup> is phenyl, biphenyl or heteroarylphenyl, wherein Ar<sup>1</sup> is optionally substituted with 1, 2 or 3 substituents selected from halo, cyano, nitro, heterocyclyl optionally substituted by one or more R<sup>13</sup>, heterocyclylalkyl optionally substituted by one or more R<sup>13</sup>, heterocyclylalkenyl optionally substituted by one or more R<sup>13</sup>, heterocyclylalkynyl optionally substituted by one or more R<sup>13</sup>, hydroxylamino, OR<sup>5</sup>, SR<sup>5</sup>, SOR<sup>6</sup>, SO<sub>2</sub>R<sup>6</sup>, COR<sup>6</sup>, COOR<sup>5</sup>, OC(O)R<sup>6</sup> or NR<sup>7</sup>R<sup>8</sup>;

Ar<sup>2</sup> is aryl or heteroaryl;

D is CR<sup>3</sup>;

A<sup>1</sup> is absent or a C<sub>1-3</sub> alkylene group;

A<sup>2</sup> is a C<sub>1-3</sub> alkylene group;

E is CO, C(O)O, C(O)NR<sup>4</sup>, SO<sub>2</sub> or a bond;

G is C<sub>1-3</sub> alkylene;

R<sup>1</sup> is H or C<sub>1-6</sub> alkyl; and

 $R^2$  is H or  $C_{1-6}$  alkyl.

Page 11 of 28

# 40. (Original) The compound of claim 1 wherein:

Ar<sup>1</sup> is phenyl, biphenyl or heteroarylphenyl, wherein Ar<sup>1</sup> is optionally substituted with 1, 2 or 3 substituents selected from halo, cyano, nitro, heterocyclyl optionally substituted by one or more R<sup>13</sup>, heterocyclylalkyl optionally substituted by one or more R<sup>13</sup>, heterocyclylalkenyl optionally substituted by one or more R<sup>13</sup>, heterocyclylalkynyl optionally substituted by one or more R<sup>13</sup>, hydroxylamino, OR<sup>5</sup>, SR<sup>5</sup>, SOR<sup>6</sup>, SO<sub>2</sub>R<sup>6</sup>, COR<sup>6</sup>, COOR<sup>5</sup>, OC(O)R<sup>6</sup> or NR<sup>7</sup>R<sup>8</sup>;

```
Ar<sup>2</sup> is aryl or heteroaryl;
D is CH;
A<sup>1</sup> is absent, CH<sub>2</sub> or CH<sub>2</sub>CH<sub>2</sub>;
A<sup>2</sup> is CH<sub>2</sub>CH<sub>2</sub> or CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>;
E is CO, SO<sub>2</sub> or a bond;
G is CH<sub>2</sub> or CH<sub>2</sub>CH<sub>2</sub>;
R<sup>1</sup> is C<sub>1.4</sub> alkyl; and
R<sup>2</sup> is H.
```

# 41. (Original) The compound of claim 1 wherein:

Ar<sup>1</sup> is phenyl, biphenyl or heteroarylphenyl, wherein Ar<sup>1</sup> is substituted with 1, 2 or 3 substituents selected from halo, cyano, nitro, heterocyclyl optionally substituted by one or more  $R^{13}$ , heterocyclylalkynyl optionally substituted by one or more  $R^{13}$ ,  $C_{1-4}$  alkoxy,  $SO_2R^6$ ,  $COR^6$ ,  $COOR^5$  or  $NR^7R^8$ ;

```
Ar<sup>2</sup> is aryl or heteroaryl;
D is CH;
A<sup>1</sup> is absent, CH<sub>2</sub> or CH<sub>2</sub>CH<sub>2</sub>;
A<sup>2</sup> is CH<sub>2</sub>CH<sub>2</sub> or CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>;
E is CO, SO<sub>2</sub> or a bond;
G is CH<sub>2</sub> or CH<sub>2</sub>CH<sub>2</sub>;
R<sup>1</sup> is C<sub>1-4</sub> alkyl; and
R<sup>2</sup> is H.
```

# 42. (Original) The compound of claim 1 selected from:

Docket No.: 74.US2.PCT

- 4-{4-[3-(3-Bromo-phenyl)-5-methyl-isoxazol-4-yl]-thiazol-2-yl}-1-phenylmethane-sulfonyl-piperidine;
- 1-(4-{4-[3-(3-Bromo-phenyl)-5-methyl-isoxazol-4-yl]-thiazol-2-yl}-piperidin-1-yl)-2-thiophen-2-yl-ethanone;
- 1-(4-{4-[3-(3-Bromo-phenyl)-5-methyl-isoxazol-4-yl]-thiazol-2-yl}-piperidin-1-yl)-2-thiophen-3-yl-ethanone;
- $1-(2-\{4-[3-(3-Bromo-phenyl)-5-methyl-isoxazol-4-yl]-thiazol-2-yl\}-pyrrolidin-1-yl)-2-thiophen-2-yl-ethanone;\\$
- l-(4-{4-[3-(3-Isopropylamino-phenyl)-5-methyl-isoxazol-4-yl]-thiazol-2-yl}-piperidin-1-yl)-2-thiophen-2-yl-ethanone;
- 1-[4-(4-{5-Methyl-3-[3-(2-morpholin-4-yl-ethylamino)-phenyl]-isoxazol-4-yl}-thiazol-2-yl)-piperidin-1-yl]-2-thiophen-2-yl-ethanone;
- 1-(4-{4-[5-Methyl-3-(3-morpholin-4-yl-phenyl)-isoxazol-4-yl]-thiazol-2-yl}-piperidin-1-yl)-2-thiophen-2-yl-ethanone;
- 1-[4-(4-{5-Methyl-3-[3-(4-methyl-piperazin-1-yl)-phenyl]-isoxazol-4-yl}-thiazol-2-yl)-piperidin-1-yl]-2-thiophen-2-yl-ethanone;
- N-[3'-(5-Methyl-4-{2-[1-(2-thiophen-2-yl-acetyl)-piperidin-4-yl]-thiazol-4-yl}-isoxazol-3-yl)-biphenyl-4-yl]-acetamide;
- N-[3'-(5-Methyl-4-{2-[1-(2-thiophen-2-yl-acetyl)-piperidin-4-yl]-thiazol-4-yl}-isoxazol-3-yl)-biphenyl-3-yl]-acetamide;
- 3'-(5-Methyl-4-{2-[1-(2-thiophen-2-yl-acetyl)-piperidin-4-yl]-thiazol-4-yl}-isoxazol-3-yl)-biphenyl-4-carboxylic acid amide;
- 3'-(5-Methyl-4-{2-[1-(2-thiophen-2-yl-acetyl)-piperidin-4-yl]-thiazol-4-yl}-isoxazol-3-yl)-biphenyl-3-carboxylic acid amide;
- 3'-{5-Methyl-4-[2-(1-phenylmethanesulfonyl-piperidin-4-yl)-thiazol-4-yl]-isoxazol-3-yl}-biphenyl-4-carboxylic acid;
- 3'-(5-Methyl-4-{2-[1-(2-thiophen-2-yl-acetyl)-piperidin-4-yl]-thiazol-4-yl}-isoxazol-3-yl)-biphenyl-4-carboxylic acid;
- 3'-(5-Methyl-4-{2-[1-(2-thiophen-2-yl-acetyl)-pyrrolidin-2-yl]-thiazol-4-yl}-isoxazol-3-yl)-biphenyl-4-carboxylic acid;
- 3'-(5-Methyl-4-{2-[1-(2-thiophen-2-yl-acetyl)-piperidin-4-yl]-thiazol-4-yl}-isoxazol-3-yl)-biphenyl-3-carboxylic acid;
- 1-(4-{4-[5-Methyl-3-(3-pyridin-4-yl-phenyl)-isoxazol-4-yl]-thiazol-2-yl}-piperidin-1-yl)-2-thiophen-2-yl-ethanone;

1-(4-{4-[5-Methyl-3-(3-pyrimidin-5-yl-phenyl)-isoxazol-4-yl]-thiazol-2-yl}-piperidin-1-yl)-2-thiophen-2-yl-ethanone;

1-(4-{4-[3-(4'-Methoxy-biphenyl-3-yl)-5-methyl-isoxazol-4-yl]-thiazol-2-yl}-piperidin-1-yl)-2-thiophen-2-yl-ethanone;

3'-(5-Methyl-4-{2-[1-(2-thiophen-2-yl-acetyl)-piperidin-4-yl]-thiazol-4-yl}-isoxazol-3-yl)-biphenyl-4-carboxylic acid dimethylamide;

3'-(5-Methyl-4-{2-[1-(2-thiophen-2-yl-acetyl)-piperidin-4-yl]-thiazol-4-yl}-isoxazol-3-yl)-biphenyl-4-carboxylic acid methylamide;

 $1-[4-(4-\{5-Methyl-3-[4'-(morpholine-4-carbonyl)-biphenyl-3-yl]-isoxazol-4-yl\}-thiazol-2-yl)-piperidin-1-yl]-2-thiophen-2-yl-ethanone;$ 

1-[4-(4-{5-Methyl-3-[3'-(morpholine-4-carbonyl)-biphenyl-3-yl]-isoxazol-4-yl}-thiazol-2-yl)-piperidin-1-yl]-2-thiophen-2-yl-ethanone;

1-(4-{4-[3-(4'-Amino-biphenyl-3-yl)-5-methyl-isoxazol-4-yl]-thiazol-2-yl}-piperidin-1-yl)-2-thiophen-2-yl-ethanone;

N-[3'-(5-Methyl-4-{2-[1-(2-thiophen-2-yl-acetyl)-piperidin-4-yl]-thiazol-4-yl}-isoxazol-3-yl)-biphenyl-4-yl]-methanesulfonamide;

1-(4-{4-[3-(4'-Methanesulfonyl-biphenyl-3-yl)-5-methyl-isoxazol-4-yl]-thiazol-2-yl}-piperidin-1-yl)-2-thiophen-2-yl-ethanone;

2,2,2-Trifluoro-N-[3'-(5-methyl-4-{2-[1-(2-thiophen-2-yl-acetyl)-piperidin-4-yl]-thiazol-4-yl}-isoxazol-3-yl)-biphenyl-3-yl]-acetamide;

1-(4-{4-[3-(3'-Methanesulfonyl-biphenyl-3-yl)-5-methyl-isoxazol-4-yl]-thiazol-2-yl}-piperidin-1-yl)-2-thiophen-2-yl-ethanone;

3'-(5-Methyl-4-{2-[1-(2-thiophen-2-yl-acetyl)-piperidin-4-yl]-thiazol-4-yl}-isoxazol-3-yl)-biphenyl-4-carbonitrile;

 $1-\{4-[4-(3-\{3-[3-(1,1-Dioxo-1\lambda 6-thiomorpholin-4-yl)-prop-1-ynyl]-phenyl\}-5-methyl-isoxazol-4-yl\}-thiazol-2-yl]-piperidin-1-yl}-2-thiophen-2-yl-ethanone;$ 

l-[4-(4-{5-Methyl-3-[4'-(1H-tetrazol-5-yl)-biphenyl-3-yl]-isoxazol-4-yl}-thiazol-2-yl)-piperidin-1-yl]-2-thiophen-2-yl-ethanone; and

 $1-[4-(4-\{3-[4'-(4,5-Dihydro-1H-imidazol-2-yl)-biphenyl-3-yl]-5-methyl-isoxazol-4-yl\}-thiazol-2-yl)-piperidin-1-yl]-2-thiophen-2-yl-ethanone;$ 

or pharmaceutically acceptable salt thereof.

Page 14 of 28

43. (Original) A composition comprising a compound of claim 1 and a pharmaceutically acceptable carrier.

44. (Original) A method of modulating the follicle stimulating hormone (FSH) receptor comprising contacting said receptor with a compound of claim 1.

- 45. (Amended) A method of activating the follicle stimulating hormone (FSH) receptor comprising contacting said receptor with a compound of claim 1 or 42.
- 46. (Original) A method of increasing the adenylyl cyclase activity or the level of 5'-monophosphate (cAMP) in a cell, cell culture or tissue expressing the follicle stimulating hormone receptor comprising contacting said cell, cell culture or tissue with a compound of claim 1.
- 47. (Original) A method of inducing ovulation in a female mammal comprising administering to said female mammal an ovulation-inducing amount of a compound of claim 1.
- 48. (Amended) A method of treating a fertility disorder in a patient comprising administering to said patient a therapeutically effective amount of a compound of claim 1 or 42.
- 49. (Original) A method of treating infertility in a female patient comprising administering to said female patient a therapeutically effective amount of a compound of claim 1.
- 50. (Cancelled) A compound according to any one of claims 1 to 42 for use in therapy.
- 51. (Cancelled) A compound according to any one of claims 1 to 42 for use in the treatment of a fertility disorder in a patient.
- 52. (Cancelled) A compound according to any one of claims 1 to 42 for use in the treatment of infertility in a female patient.
- 53. (Cancelled) A compound according to any one of claims 1-to 42 for use in the preparation of a medicament for use in therapy.

Page 15 of 28

54. (Cancelled) A compound according to any one of claims 1 to 42 for use in the preparation of a medicament for use in the treatment of a fertility disorder in a patient.

- 55. (Cancelled) A compound according to any one of claims 1 to 42 for use in the preparation of a medicament for use in the treatment of infertility in a female patient.
- 56. (Cancelled) Use of a compound according to any one of claims 1 to 42 for the manufacture of a medicament.
- 57. (Cancelled) Use of a compound according to any one of claims 1 to 42 for the manufacture of a medicament for the treatment of a fertility disorder in a patient.
- 58. (Cancelled) Use of a compound according to any one of claims 1 to 42 for the manufacture of a medicament for the treatment of infertility in a female patient.

Page 16 of 28

Docket No.: 74.US2.PCT

#### **Clean Copy of Claims:**

#### 1. (Original) A compound of Formula I:

$$O$$
 $Ar^1$ 
 $R^2$ 
 $S$ 
 $A^1$ 
 $A^2$ 
 $N$ 
 $E$ 
 $G$ 
 $A^2$ 

or a pharmaceutically acceptable salt, hydrate or solvate thereof, wherein:

Ar<sup>1</sup> is aryl, heteroaryl, biaryl, biheteroaryl, arylheteroaryl or heteroarylaryl, wherein Ar<sup>1</sup> is optionally substituted with one or more substituents selected from halo, cyano, nitro, C<sub>1-6</sub> alkyl, C<sub>1-6</sub> haloalkyl, C<sub>2-6</sub> alkenyl, C<sub>2-6</sub> alkynyl, carbocyclyl optionally substituted by one or more R<sup>13</sup>, heterocyclyl optionally substituted by one or more R<sup>13</sup>, carbocyclylalkyl optionally substituted by one or more R<sup>13</sup>, carbocyclylalkenyl optionally substituted by one or more R<sup>13</sup>, carbocyclylalkynyl optionally substituted by one or more R<sup>13</sup>, heterocyclylalkyl optionally substituted by one or more R<sup>13</sup>, heterocyclylalkenyl optionally substituted by one or more R<sup>13</sup>, heterocyclylalkynyl optionally substituted by one or more R<sup>13</sup>, hydroxylamino, OR<sup>5</sup>, SR<sup>5</sup>, SOR<sup>6</sup>, SO<sub>2</sub>R<sup>6</sup>, COR<sup>6</sup>, COOR<sup>5</sup>, OC(O)R<sup>6</sup> or NR<sup>7</sup>R<sup>8</sup>;

Ar<sup>2</sup> is aryl or heteroaryl, each optionally substituted with one or more substituents selected from halo, cyano, nitro, C<sub>1-6</sub> alkyl, C<sub>1-6</sub> haloalkyl, C<sub>2-6</sub> alkenyl, C<sub>2-6</sub> alkynyl, carbocyclyl optionally substituted by one or more R<sup>14</sup>, heterocyclyl optionally substituted by one or more R<sup>14</sup>. hydroxylamino, OR<sup>9</sup>, SR<sup>9</sup>, SOR<sup>10</sup>, SO<sub>2</sub>R<sup>10</sup>, COR<sup>10</sup>, COOR<sup>9</sup>, OC(O)R<sup>10</sup> or NR<sup>11</sup>R<sup>12</sup>;

D is N, C or CR<sup>3</sup>:

--- is a single bond when D is N or CR<sup>3</sup>;

--- is a double bond when D is C;

A<sup>1</sup> is absent or a C<sub>1-3</sub> straight-chain aliphatic group optionally substituted with one or more substituents selected from halo, C<sub>1.4</sub> alkyl, C<sub>1.4</sub> haloalkyl, C<sub>1.4</sub> alkoxy, C<sub>1.4</sub> haloalkoxy, amino, (C<sub>1.6</sub> alkyl)amino, di(C<sub>1-6</sub> alkyl)amino, hydroxy, carboxy, (C<sub>1-4</sub> alkoxy)carbonyl, or cyano;

A<sup>2</sup> is C<sub>1-4</sub> straight-chain aliphatic group optionally substituted with one or more substituents selected from halo, C<sub>1-4</sub> alkyl, C<sub>1-4</sub> haloalkyl, C<sub>1-4</sub> alkoxy, C<sub>1-4</sub> haloalkoxy, amino, (C<sub>1-6</sub> alkyl)amino,  $di(C_{1-6} alkyl)amino, hydroxy, carboxy, (C_{1-4} alkoxy)carbonyl, or cyano;$ 

E is CO, C(O)O, C(O)NR<sup>4</sup>, NR<sup>4</sup>CONR<sup>4</sup>, SO, SO<sub>2</sub>, SONR<sup>4</sup>, SO<sub>2</sub>NR<sup>4</sup>, or a bond;

G is  $C_{1-3}$  alkylene,  $C_{2-3}$  alkenylene or  $C_{2-3}$  alkynylene optionally substituted with one or more substituents selected from halo,  $C_{1-4}$  alkyl,  $C_{1-4}$  haloalkyl,  $C_{1-4}$  alkoxy,  $C_{1-4}$  haloalkoxy, amino,  $(C_{1-4}$  alkyl)amino, di $(C_{1-4}$  alkyl)amino, hydroxy, carboxy,  $(C_{1-4}$  alkoxy)carbonyl, or cyano;

Docket No.: 74.US2.PCT

 $R^1$  is H,  $C_{1-6}$  alkyl,  $C_{2-6}$  alkenyl or  $C_{2-6}$  alkynyl, wherein  $R^1$  is optionally substituted with one or more substituents selected from halo, OH, SH, nitro, cyano,  $C_{1-4}$  haloalkyl,  $C_{1-5}$  acyl,  $C_{1-5}$  acyloxy,  $C_{1-4}$  alkoxy,  $C_{1-4}$  thioalkoxy,  $C_{1-4}$  haloalkoxy, amino,  $(C_{1-4}$  alkyl)amino, di( $C_{1-4}$  alkyl)amino, aminocarbonyl,  $(C_{1-4}$  alkyl)aminocarbonyl,  $(C_{1-4}$  alkyl)aminocarbonyl,  $(C_{1-4}$  alkylsulfinyl,  $C_{1-4}$  alkylsulfinyl,  $(C_{1-4}$  alkyl)aminosulfonyl, aminosulfonyl,  $(C_{1-4}$  alkyl)aminosulfonyl, di( $(C_{1-4}$  alkyl)aminosulfonyl, ureido,  $(C_{1-4}$  alkyl)ureido, thioureido,  $(C_{1-4}$  alkyl)aminosulfonyl, and hydroxylamino;

 $R^2$  is H,  $C_{1-6}$  alkyl,  $C_{2-6}$  alkenyl or  $C_{2-6}$  alkynyl, wherein  $R^2$  is optionally substituted with one or more substituents selected from halo, OH, SH, nitro, cyano,  $C_{1-4}$  haloalkyl,  $C_{1-5}$  acyl,  $C_{1-5}$  acyloxy,  $C_{1-4}$  alkoxy,  $C_{1-4}$  thioalkoxy,  $C_{1-4}$  haloalkoxy, amino,  $(C_{1-4}$  alkyl)amino, di( $C_{1-4}$  alkyl)amino, aminocarbonyl,  $(C_{1-4}$  alkyl)aminocarbonyl,  $(C_{1-4}$  alkyl)aminocarbonyl,  $(C_{1-4}$  alkylsulfinyl,  $(C_{1-4}$  alkylsulfinyl,  $(C_{1-4}$  alkyl)aminosulfonyl, aminosulfonyl,  $(C_{1-4}$  alkyl)aminosulfonyl, di( $(C_{1-4}$  alkyl)aminosulfonyl, ureido,  $(C_{1-4}$  alkyl)ureido, thioureido,  $(C_{1-4}$  alkyl)thioureido, carboxy,  $(C_{1-6}$  alkoxy)carbonyl, and hydroxylamino;

or  $R^1$  and  $R^2$  together with the carbon atoms to which they are attached and the two carbon atoms through which the isoxazole and thiazole moieties of the core are joined form a fused  $C_{5-7}$  carbocyclyl group or fused 5-7 membered heterocyclyl group optionally substituted with one or more substituents selected from halo,  $C_{1-4}$  alkyl,  $C_{1-4}$  haloalkyl,  $C_{1-4}$  alkoxy,  $C_{1-4}$  haloalkoxy, amino,  $(C_{1-4}$  alkyl)amino, di $(C_{1-4}$  alkyl)amino, hydroxy, carboxy,  $(C_{1-4}$  alkoxy)carbonyl, or cyano;

 $R^3$  is H or  $C_{1-6}$  alkyl;

R<sup>4</sup>, at each independent occurrence, is H or C<sub>1-4</sub> alkyl;

R<sup>5</sup> and R<sup>9</sup> are each, independently, H, C<sub>1-8</sub> alkyl, C<sub>1-8</sub> haloalkyl, C<sub>2-8</sub> alkenyl, C<sub>2-8</sub> alkynyl, aryl, heteroaryl, C<sub>3-7</sub> cycloalkyl, 5-7 membered heterocycloalkyl, arylalkyl, heteroarylalkyl, (C<sub>3-7</sub> cycloalkyl)alkyl or (5-7 membered heterocycloalkyl)alkyl;

R<sup>6</sup> and R<sup>10</sup> are each, independently, H, C<sub>1-8</sub> alkyl, C<sub>1-8</sub> haloalkyl, C<sub>2-8</sub> alkenyl, C<sub>2-8</sub> alkynyl, aryl, heteroaryl, C<sub>3-7</sub> cycloalkyl, 5-7 membered heterocycloalkyl, arylalkyl, heteroarylalkyl, (C<sub>3-7</sub> cycloalkyl)alkyl, (5-7 membered heterocycloalkyl)alkyl, amino, (C<sub>1-4</sub> alkyl)amino, di(C<sub>1-4</sub> alkyl)amino,

Page 18 of 28

 $R^7$  and  $R^8$  are each, independently, H,  $C_{1-8}$  alkyl,  $C_{2-8}$  alkenyl,  $C_{2-8}$  alkynyl, aryl, heteroaryl,  $C_{3-7}$  cycloalkyl, 5-7 membered heterocycloalkyl, arylalkyl, heteroarylalkyl,  $(C_{3-7}$  cycloalkyl)alkyl,  $(S_{3-7}$  cycloalkyl)alkyl,  $(C_{1-8}$  alkyl)carbonyl,  $(C_{1-8}$  haloalkyl)carbonyl,  $(C_{1-8}$  haloalkyl)carbonyl,  $(C_{1-8}$  haloalkoxy)carbonyl,  $(C_{1-4}$  alkyl)sulfonyl,  $(C_{1-4}$  haloalkyl)sulfonyl or arylsulfonyl;

Docket No.: 74.US2.PCT

or R<sup>7</sup> and R<sup>8</sup>, together with the N atom to which they are attached form a 5-7 membered heterocycloalkyl group;

 $R^{11}$  and  $R^{12}$  are each, independently, H,  $C_{1-8}$  alkyl,  $C_{2-8}$  alkenyl,  $C_{2-8}$  alkynyl, aryl, heteroaryl,  $C_{3-7}$  cycloalkyl, 5-7 membered heterocycloalkyl, arylalkyl, heteroarylalkyl,  $(C_{3-7}$  cycloalkyl)alkyl, (5-7 membered heterocycloalkyl)alkyl,  $(C_{1-8}$  alkyl)carbonyl,  $(C_{1-8}$  haloalkyl)carbonyl,  $(C_{1-8}$  haloalkoxy)carbonyl,  $(C_{1-8}$  haloalkoxy)carbonyl,  $(C_{1-4}$  alkyl)sulfonyl,  $(C_{1-4}$  haloalkyl)sulfonyl or arylsulfonyl;

or R<sup>11</sup> and R<sup>12</sup>, together with the N atom to which they are attached form a 5-7 membered heterocycloalkyl group; and

 $R^{13}$  and  $R^{14}$  are each, independently, halo, cyano, nitro,  $C_{1\cdot4}$  alkyl,  $C_{1\cdot4}$  haloalkyl,  $C_{1\cdot4}$  alkoxy,  $C_{1\cdot4}$  haloalkoxy, amino,  $(C_{1\cdot4}$  alkyl)amino, di $(C_{1\cdot4}$  alkyl)amino, hydroxy, carboxy,  $(C_{1\cdot4}$  alkoxy)carbonyl,  $C_{1\cdot4}$  acyloxy, aminocarbonyl,  $(C_{1\cdot4}$  alkyl)aminocarbonyl, or di $(C_{1\cdot4}$  alkyl)aminocarbonyl.

- 2. (Original) The compound of claim 1 wherein  $Ar^1$  is aryl, heteroaryl, biaryl, biheteroaryl, arylheteroaryl or heteroarylaryl, wherein  $Ar^1$  is substituted with 1, 2 or 3 substituents selected from halo, cyano, nitro,  $C_{1-6}$  alkyl,  $C_{1-6}$  haloalkyl,  $C_{2-6}$  alkenyl,  $C_{2-6}$  alkynyl, carbocyclyl optionally substituted by one or more  $R^{13}$ , heterocyclyl optionally substituted by one or more  $R^{13}$ , carbocyclylalkyl optionally substituted by one or more  $R^{13}$ , carbocyclylalkynyl optionally substituted by one or more  $R^{13}$ , heterocyclylalkyl optionally substituted by one or more  $R^{13}$ , heterocyclylalkyl optionally substituted by one or more  $R^{13}$ , heterocyclylalkynyl optionally substituted by one or more  $R^{13}$ , heterocyclylalkynyl optionally substituted by one or more  $R^{13}$ , heterocyclylalkynyl optionally substituted by one or more  $R^{13}$ , hydroxylamino,  $R^{13}$ , hoterocyclylalkynyl optionally substituted by one or more  $R^{13}$ , hydroxylamino,  $R^{13}$ , hoterocyclylalkynyl optionally substituted by one or more  $R^{13}$ , hydroxylamino,  $R^{13}$ , hoterocyclylalkynyl optionally substituted by one or more  $R^{13}$ , hydroxylamino,  $R^{13}$ , hoterocyclylalkynyl optionally substituted by one or more  $R^{13}$ , hydroxylamino,  $R^{13}$ , hydroxylamino, hydrox
- 3. (Original) The compound of claim 1 wherein Ar<sup>1</sup> is aryl, heteroaryl, biaryl, biheteroaryl, arylheteroaryl or heteroarylaryl, wherein Ar<sup>1</sup> is optionally substituted with one or more substituents selected from halo, cyano, nitro, heterocyclyl optionally substituted by one or more R<sup>13</sup>, heterocyclylalkyl optionally substituted by one or more R<sup>13</sup>, heterocyclylalkenyl optionally

Page 19 of 28

substituted by one or more R<sup>13</sup>, heterocyclylalkynyl optionally substituted by one or more R<sup>13</sup>, hydroxylamino, OR<sup>5</sup>, SR<sup>5</sup>, SOR<sup>6</sup>, SO<sub>2</sub>R<sup>6</sup>, COR<sup>6</sup>, COOR<sup>5</sup>, OC(O)R<sup>6</sup> or NR<sup>7</sup>R<sup>8</sup>.

Docket No.: 74.US2.PCT

- 4. (Original) The compound of claim 1 wherein Ar<sup>1</sup> is aryl, biaryl or heteroarylaryl, wherein Ar<sup>1</sup> is optionally substituted with one or more substituents selected from halo, cyano, nitro, C<sub>1-6</sub> alkyl, C<sub>1-6</sub> haloalkyl, C<sub>2-6</sub> alkenyl, C<sub>2-6</sub> alkynyl, carbocyclyl optionally substituted by one or more R<sup>13</sup>, heterocyclyl optionally substituted by one or more R<sup>13</sup>, carbocyclylalkyl optionally substituted by one or more R<sup>13</sup>, carbocyclylalkynyl optionally substituted by one or more R<sup>13</sup>, heterocyclylalkyl optionally substituted by one or more R<sup>13</sup>, heterocyclylalkenyl optionally substituted by one or more R<sup>13</sup>, heterocyclylalkynyl optionally substituted by one or more R<sup>13</sup>, heterocyclylalkynyl optionally substituted by one or more R<sup>13</sup>, heterocyclylalkynyl optionally substituted by one or more R<sup>13</sup>, hydroxylamino, OR<sup>5</sup>, SR<sup>5</sup>, SOR<sup>6</sup>, SO<sub>2</sub>R<sup>6</sup>, COR<sup>6</sup>, COOR<sup>5</sup>, OC(O)R<sup>6</sup> or NR<sup>7</sup>R<sup>8</sup>.
- 5. (Original) The compound of claim 1 wherein Ar<sup>1</sup> is phenyl, biphenyl or heteroarylphenyl, wherein Ar<sup>1</sup> is optionally substituted with one or more substituents selected from halo, cyano, nitro, C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>1</sub>-C<sub>6</sub> haloalkyl, C<sub>2</sub>-C<sub>6</sub> alkenyl, C<sub>2</sub>-C<sub>6</sub> alkynyl, carbocyclyl optionally substituted by one or more R<sup>13</sup>, heterocyclyl optionally substituted by one or more R<sup>13</sup>, carbocyclylalkyl optionally substituted by one or more R<sup>13</sup>, carbocyclylalkynyl optionally substituted by one or more R<sup>13</sup>, heterocyclylalkynyl optionally substituted by one or more R<sup>13</sup>, heterocyclylalkynyl optionally substituted by one or more R<sup>13</sup>, heterocyclylalkynyl optionally substituted by one or more R<sup>13</sup>, hydroxylamino, OR<sup>5</sup>, SR<sup>5</sup>, SOR<sup>6</sup>, SO<sub>2</sub>R<sup>6</sup>, COR<sup>6</sup>, COOR<sup>5</sup>, OC(O)R<sup>6</sup> or NR<sup>7</sup>R<sup>8</sup>.
- 6. (Original) The compound of claim 1 wherein Ar<sup>1</sup> is phenyl, biphenyl or heteroarylphenyl, wherein Ar<sup>1</sup> is optionally substituted with 1, 2 or 3 substituents selected from halo, cyano, nitro, heterocyclyl optionally substituted by one or more R<sup>13</sup>, heterocyclylalkyl optionally substituted by one or more R<sup>13</sup>, heterocyclylalkenyl optionally substituted by one or more R<sup>13</sup>, heterocyclylalkynyl optionally substituted by one or more R<sup>13</sup>, hydroxylamino, OR<sup>5</sup>, SR<sup>5</sup>, SOR<sup>6</sup>, SO<sub>2</sub>R<sup>6</sup>, COR<sup>6</sup>, COOR<sup>5</sup>, OC(O)R<sup>6</sup> or NR<sup>7</sup>R<sup>8</sup>.
- 7. (Original) The compound of claim 1 wherein Ar<sup>1</sup> is phenyl, biphenyl or heteroarylphenyl, wherein Ar<sup>1</sup> is substituted with 1, 2 or 3 substituents selected from halo, cyano, nitro, heterocyclyl optionally substituted by one or more R<sup>13</sup>, heterocyclylalkynyl optionally substituted by one or more R<sup>13</sup>, C<sub>1-4</sub> alkoxy, SO<sub>2</sub>R<sup>6</sup>, COR<sup>6</sup>, COOR<sup>5</sup> or NR<sup>7</sup>R<sup>8</sup>.

Page 20 of 28

Docket No.: 74.US2.PCT

The compound of claim 1 wherein Ar<sup>2</sup> is aryl or heteroaryl, each optionally substituted with 1, 2 or 3 substituents selected from halo, cyano, nitro, C<sub>1-6</sub> alkyl, C<sub>1-6</sub> haloalkyl, C<sub>2-6</sub> alkenyl, C<sub>2-6</sub> alkynyl, carbocyclyl optionally substituted by one or more R<sup>14</sup>, heterocyclyl optionally substituted by one or more R<sup>14</sup>, hydroxylamino, OR<sup>9</sup>, SR<sup>9</sup>, SOR<sup>10</sup>, SO<sub>2</sub>R<sup>10</sup>, COR<sup>10</sup>, COOR<sup>9</sup>, OC(O)R<sup>10</sup> or NR<sup>11</sup>R<sup>12</sup>.

- 9. (Original) The compound of claim 1 wherein Ar<sup>2</sup> is aryl or heteroaryl.
- The compound of claim 1 wherein Ar<sup>2</sup> is heteroaryl. 10. (Original)
- 11. (Original) The compound of claim 1 wherein Ar<sup>2</sup> is thienyl.
- The compound of claim 1 wherein  $Ar^2$  is aryl. 12. (Original)
- 13. (Original) The compound of claim 1 wherein Ar<sup>2</sup> is phenyl.
- 14. (Original) The compound of claim 1 wherein D is CR<sup>3</sup>.
- 15. (Original) The compound of claim 1 wherein D is CH.
- 16. (Original) The compound of claim 1 wherein  $A^1$  is a  $C_{1-3}$  alkylene group.
- 17. (Original) The compound of claim 1 wherein A<sup>1</sup> is CH<sub>2</sub> or CH<sub>2</sub>CH<sub>2</sub>.
- The compound of claim 1 wherein A<sup>1</sup> is absent. 18. (Original)
- The compound of claim 1 wherein D is CR<sup>3</sup> and A<sup>2</sup> is a C<sub>1-3</sub> alkylene group. 19. (Original)
- The compound of claim 1 wherein D is CR<sup>3</sup> and A<sup>2</sup> is CH<sub>2</sub>CH<sub>2</sub> or CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>. 20. (Original)
- The compound of claim 1 wherein D is CR<sup>3</sup>, A<sup>1</sup> is CH<sub>2</sub>CH<sub>2</sub>, and A<sup>2</sup> is CH<sub>2</sub>CH<sub>2</sub>. 21. (Original)
- The compound of claim 1 wherein D is CR<sup>3</sup>, A<sup>1</sup> is absent, and A<sup>2</sup> is CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>. 22. (Original)

Page 21 of 28

23. (Original) The compound of claim 1 wherein E is CO, C(O)O, C(O)NR<sup>4</sup>, SO<sub>2</sub> or a bond.

- 24. (Original) The compound of claim 1 wherein E is CO or SO<sub>2</sub>.
- 25. (Original) The compound of claim 1 wherein E is CO.
- 26. (Original) The compound of claim 1 wherein G is  $C_{1-3}$  alkylene.
- 27. (Original) The compound of claim 1 wherein G is CH<sub>2</sub> or CH<sub>2</sub>CH<sub>2</sub>.
- 28. (Original) The compound of claim 1 wherein G is CH<sub>2</sub>.
- 29. (Original) The compound of claim 1 wherein R<sup>1</sup> is H or C<sub>1-4</sub> alkyl.
- 30. (Original) The compound of claim 1 wherein R<sup>1</sup> is methyl.

#### 31. (Original) The compound of claim 1 wherein:

 $R^1$  is H,  $C_{1-6}$  alkyl,  $C_{2-6}$  alkenyl or  $C_{2-6}$  alkynyl, wherein  $R^1$  is optionally substituted with one or more substituents selected from halo, OH, SH, nitro, cyano,  $C_{1-4}$  haloalkyl,  $C_{1-5}$  acyl,  $C_{1-5}$  acyloxy,  $C_{1-4}$  alkoxy,  $C_{1-4}$  thioalkoxy,  $C_{1-4}$  haloalkoxy, amino,  $(C_{1-4}$  alkyl)amino, di( $C_{1-4}$  alkyl)amino, di( $C_{1-4}$  alkyl)aminocarbonyl,  $(C_{1-4}$  alkyl)aminocarbonyl,  $(C_{1-4}$  alkylsulfinyl,  $C_{1-4}$  alkylsulfinyl,  $(C_{1-4}$  alkyl)aminosulfonyl, aminosulfonyl,  $(C_{1-4}$  alkyl)aminosulfonyl, di( $(C_{1-4}$  alkyl)aminosulfonyl, ureido,  $(C_{1-4}$  alkyl)ureido, thioureido,  $(C_{1-4}$  alkyl)thioureido, carboxy,  $(C_{1-6}$  alkoxy)carbonyl, and hydroxylamino; and

 $R^2$  is H,  $C_{1-6}$  alkyl,  $C_{2-6}$  alkenyl or  $C_{2-6}$  alkynyl, wherein  $R^2$  is optionally substituted with one or more substituents selected from halo, OH, SH, nitro, cyano,  $C_{1-4}$  haloalkyl,  $C_{1-5}$  acyl,  $C_{1-5}$  acyloxy,  $C_{1-4}$  alkoxy,  $C_{1-4}$  thioalkoxy,  $C_{1-4}$  haloalkoxy, amino,  $(C_{1-4}$  alkyl)amino, di( $C_{1-4}$  alkyl)amino, aminocarbonyl,  $(C_{1-4}$  alkyl)aminocarbonyl,  $(C_{1-4}$  alkyl)aminocarbonyl,  $(C_{1-4}$  alkylsulfinyl,  $C_{1-4}$  alkylsulfinyl,  $(C_{1-4}$  alkyl)aminosulfonyl, aminosulfonyl,  $(C_{1-4}$  alkyl)aminosulfonyl, di( $(C_{1-4}$  alkyl)aminosulfonyl, ureido,  $(C_{1-4}$  alkyl)ureido, thioureido,  $(C_{1-4}$  alkyl)aminosulfonyl, and hydroxylamino.

Page 22 of 28

32. (Original) The compound of claim 1 wherein  $R^2$  is H or  $C_{1-4}$  alkyl.

- 33. (Original) The compound of claim 1 wherein  $R^2$  is H.
- 34. (Original) The compound of claim 1 wherein R<sup>3</sup> is H.
- 35. (Original) The compound of claim 1 wherein R<sup>4</sup>, at each independent occurrence, is H.
- 36. (Original) The compound of claim 1 wherein:

D is CR<sup>3</sup>;

 $A^1$  is a absent or a  $C_{1-3}$  alkylene group;

A<sup>2</sup> is a C<sub>1-3</sub> alkylene group;

E is CO, C(O)O, C(O)NR<sup>4</sup>, SO<sub>2</sub> or a bond;

G is C<sub>1-3</sub> alkylene;

R1 is H or C1-6 alkyl; and

 $R^2$  is H or  $C_{1-6}$  alkyl.

#### 37. (Original) The compound of claim 1 wherein:

Ar<sup>2</sup> is aryl or heteroaryl, each optionally substituted with 1, 2 or 3 substituents selected from halo, cyano, nitro, C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>1</sub>-C<sub>6</sub> haloalkyl, C<sub>2</sub>-C<sub>6</sub> alkenyl, C<sub>2</sub>-C<sub>6</sub> alkynyl, carbocyclyl optionally substituted by one or more R<sup>14</sup>, heterocyclyl optionally substituted by one or more R<sup>14</sup>, hydroxylamino, OR<sup>9</sup>, SR<sup>9</sup>, SOR<sup>10</sup>, SO<sub>2</sub>R<sup>10</sup>, COR<sup>10</sup>, COOR<sup>9</sup>, OC(O)R<sup>10</sup> or NR<sup>11</sup>R<sup>12</sup>;

D is CR<sup>3</sup>:

 $A^1$  is absent or a  $C_{1-3}$  alkylene group;

 $A^2$  is a  $C_{1-3}$  alkylene group;

E is CO, C(O)O, C(O)NR<sup>4</sup>, SO<sub>2</sub> or a bond;

G is C<sub>1-3</sub> alkylene;

R<sup>1</sup> is H or C<sub>1-6</sub> alkyl; and

 $R^2$  is H or  $C_{1-6}$  alkyl.

## 38. (Original) The compound of claim 1 wherein:

Ar<sup>1</sup> is phenyl, biphenyl or heteroarylphenyl, wherein Ar<sup>1</sup> is optionally substituted with one or more substituents selected from halo, cyano, nitro, C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>1</sub>-C<sub>6</sub> haloalkyl, C<sub>2</sub>-C<sub>6</sub> alkenyl, C<sub>2</sub>-

Page 23 of 28

 $C_6$  alkynyl, carbocyclyl optionally substituted by one or more  $R^{13}$ , heterocyclyl optionally substituted by one or more  $R^{13}$ , carbocyclylalkyl optionally substituted by one or more  $R^{13}$ , carbocyclylalkynyl optionally substituted by one or more  $R^{13}$ , heterocyclylalkyl optionally substituted by one or more  $R^{13}$ , heterocyclylalkyl optionally substituted by one or more  $R^{13}$ , heterocyclylalkyl optionally substituted by one or more  $R^{13}$ , heterocyclylalkynyl optionally substituted by one or more  $R^{13}$ , hydroxylamino,  $OR^5$ ,  $SR^5$ ,  $SOR^6$ ,  $SO_2R^6$ ,  $COR^6$ ,  $COOR^5$ ,  $OC(O)R^6$  or  $NR^7R^8$ ;

Docket No.: 74.US2.PCT

Ar<sup>2</sup> is aryl or heteroaryl;
D is CR<sup>3</sup>;
A<sup>1</sup> is absent or a C<sub>1-3</sub> alkylene group;
A<sup>2</sup> is a C<sub>1-3</sub> alkylene group;
E is CO, C(O)O, C(O)NR<sup>4</sup>, SO<sub>2</sub> or a bond;
G is C<sub>1-3</sub> alkylene;
R<sup>1</sup> is H or C<sub>1-6</sub> alkyl; and
R<sup>2</sup> is H or C<sub>1-6</sub> alkyl.

#### 39. (Original) The compound of claim 1 wherein:

Ar<sup>1</sup> is phenyl, biphenyl or heteroarylphenyl, wherein Ar<sup>1</sup> is optionally substituted with 1, 2 or 3 substituents selected from halo, cyano, nitro, heterocyclyl optionally substituted by one or more R<sup>13</sup>, heterocyclylalkyl optionally substituted by one or more R<sup>13</sup>, heterocyclylalkenyl optionally substituted by one or more R<sup>13</sup>, heterocyclylalkynyl optionally substituted by one or more R<sup>13</sup>, hydroxylamino, OR<sup>5</sup>, SR<sup>5</sup>, SOR<sup>6</sup>, SO<sub>2</sub>R<sup>6</sup>, COR<sup>6</sup>, COOR<sup>5</sup>, OC(O)R<sup>6</sup> or NR<sup>7</sup>R<sup>8</sup>;

Ar<sup>2</sup> is aryl or heteroaryl;
D is CR<sup>3</sup>;
A<sup>1</sup> is absent or a C<sub>1-3</sub> alkylene group;
A<sup>2</sup> is a C<sub>1-3</sub> alkylene group;
E is CO, C(O)O, C(O)NR<sup>4</sup>, SO<sub>2</sub> or a bond;
G is C<sub>1-3</sub> alkylene;
R<sup>1</sup> is H or C<sub>1-6</sub> alkyl; and
R<sup>2</sup> is H or C<sub>1-6</sub> alkyl.

# 40. (Original) The compound of claim 1 wherein:

Ar<sup>1</sup> is phenyl, biphenyl or heteroarylphenyl, wherein Ar<sup>1</sup> is optionally substituted with 1, 2 or 3 substituents selected from halo, cyano, nitro, heterocyclyl optionally substituted by one or more R<sup>13</sup>, heterocyclylalkyl optionally substituted by one or more R<sup>13</sup>, heterocyclylalkyl optionally

Page 24 of 28

substituted by one or more R<sup>13</sup>, heterocyclylalkynyl optionally substituted by one or more R<sup>13</sup>, hydroxylamino, OR<sup>5</sup>, SR<sup>5</sup>, SOR<sup>6</sup>, SO<sub>2</sub>R<sup>6</sup>, COR<sup>6</sup>, COOR<sup>5</sup>, OC(O)R<sup>6</sup> or NR<sup>7</sup>R<sup>8</sup>;

Ar<sup>2</sup> is aryl or heteroaryl;

D is CH;

A<sup>1</sup> is absent, CH<sub>2</sub> or CH<sub>2</sub>CH<sub>2</sub>;

A<sup>2</sup> is CH<sub>2</sub>CH<sub>2</sub> or CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>;

E is CO, SO<sub>2</sub> or a bond;

G is CH<sub>2</sub> or CH<sub>2</sub>CH<sub>2</sub>;

 $R^1$  is  $C_{1-4}$  alkyl; and

 $R^2$  is H.

### 41. (Original) The compound of claim 1 wherein:

Ar<sup>1</sup> is phenyl, biphenyl or heteroarylphenyl, wherein Ar<sup>1</sup> is substituted with 1, 2 or 3 substituents selected from halo, cyano, nitro, heterocyclyl optionally substituted by one or more  $R^{13}$ , heterocyclylalkynyl optionally substituted by one or more  $R^{13}$ ,  $C_{1.4}$  alkoxy,  $SO_2R^6$ ,  $COR^6$ ,  $COOR^5$  or  $NR^7R^8$ :

Ar<sup>2</sup> is aryl or heteroaryl;

D is CH;

A<sup>1</sup> is absent, CH<sub>2</sub> or CH<sub>2</sub>CH<sub>2</sub>;

A<sup>2</sup> is CH<sub>2</sub>CH<sub>2</sub> or CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>;

E is CO, SO<sub>2</sub> or a bond;

G is CH<sub>2</sub> or CH<sub>2</sub>CH<sub>2</sub>;

R<sup>1</sup> is C<sub>1-4</sub> alkyl; and

 $R^2$  is H.

# 42. (Original) The compound of claim 1 selected from:

Docket No.: 74.US2.PCT

- 4-{4-[3-(3-Bromo-phenyl)-5-methyl-isoxazol-4-yl]-thiazol-2-yl}-1-phenylmethane-sulfonyl-piperidine;
- $1-(4-\{4-[3-(3-Bromo-phenyl)-5-methyl-isoxazol-4-yl]-thiazol-2-yl\}-piperidin-1-yl)-2-thiophen-2-yl-ethanone;$
- $\label{lem:condition} 1-(4-\{4-[3-(3-Bromo-phenyl)-5-methyl-isoxazol-4-yl]-thiazol-2-yl}-piperidin-1-yl)-2-thiophen-3-yl-ethanone;$
- $1-(2-\{4-[3-(3-Bromo-phenyl)-5-methyl-isoxazol-4-yl]-thiazol-2-yl\}-pyrrolidin-1-yl)-2-thiophen-2-yl-ethanone;\\$
- 1-(4-{4-[3-(3-Isopropylamino-phenyl)-5-methyl-isoxazol-4-yl]-thiazol-2-yl}-piperidin-1-yl)-2-thiophen-2-yl-ethanone;
- 1-[4-(4-{5-Methyl-3-[3-(2-morpholin-4-yl-ethylamino)-phenyl]-isoxazol-4-yl}-thiazol-2-yl)-piperidin-1-yl]-2-thiophen-2-yl-ethanone;
- 1-(4-{4-[5-Methyl-3-(3-morpholin-4-yl-phenyl)-isoxazol-4-yl]-thiazol-2-yl}-piperidin-1-yl)-2-thiophen-2-yl-ethanone;
- 1-[4-(4-{5-Methyl-3-[3-(4-methyl-piperazin-1-yl)-phenyl]-isoxazol-4-yl}-thiazol-2-yl)-piperidin-1-yl]-2-thiophen-2-yl-ethanone;
- N-[3'-(5-Methyl-4-{2-[1-(2-thiophen-2-yl-acetyl)-piperidin-4-yl]-thiazol-4-yl}-isoxazol-3-yl)-biphenyl-4-yl]-acetamide;
- N-[3'-(5-Methyl-4-{2-[1-(2-thiophen-2-yl-acetyl)-piperidin-4-yl]-thiazol-4-yl}-isoxazol-3-yl)-biphenyl-3-yl]-acetamide;
- 3'-(5-Methyl-4-{2-[1-(2-thiophen-2-yl-acetyl)-piperidin-4-yl]-thiazol-4-yl}-isoxazol-3-yl)-biphenyl-4-carboxylic acid amide:
- 3'-(5-Methyl-4-{2-[1-(2-thiophen-2-yl-acetyl)-piperidin-4-yl]-thiazol-4-yl}-isoxazol-3-yl)-biphenyl-3-carboxylic acid amide;
- 3'-{5-Methyl-4-[2-(1-phenylmethanesulfonyl-piperidin-4-yl)-thiazol-4-yl]-isoxazol-3-yl}-biphenyl-4-carboxylic acid;
- $3'-(5-Methyl-4-\{2-[1-(2-thiophen-2-yl-acetyl)-piperidin-4-yl]-thiazol-4-yl\}-isoxazol-3-yl)-biphenyl-4-carboxylic acid;$
- 3'-(5-Methyl-4-{2-[1-(2-thiophen-2-yl-acetyl)-pyrrolidin-2-yl]-thiazol-4-yl}-isoxazol-3-yl)-biphenyl-4-carboxylic acid;
- 3'-(5-Methyl-4-{2-[1-(2-thiophen-2-yl-acetyl)-piperidin-4-yl]-thiazol-4-yl}-isoxazol-3-yl)-biphenyl-3-carboxylic acid;
- 1-(4-{4-[5-Methyl-3-(3-pyridin-4-yl-phenyl)-isoxazol-4-yl]-thiazol-2-yl}-piperidin-1-yl)-2-thiophen-2-yl-ethanone;

Page 26 of 28

1-(4-{4-[5-Methyl-3-(3-pyrimidin-5-yl-phenyl)-isoxazol-4-yl]-thiazol-2-yl}-piperidin-1-yl)-2-thiophen-2-yl-ethanone;

1-(4-{4-[3-(4'-Methoxy-biphenyl-3-yl)-5-methyl-isoxazol-4-yl]-thiazol-2-yl}-piperidin-1-yl)-2-thiophen-2-yl-ethanone;

3'-(5-Methyl-4-{2-[1-(2-thiophen-2-yl-acetyl)-piperidin-4-yl]-thiazol-4-yl}-isoxazol-3-yl)-biphenyl-4-carboxylic acid dimethylamide;

3'-(5-Methyl-4-{2-[1-(2-thiophen-2-yl-acetyl)-piperidin-4-yl]-thiazol-4-yl}-isoxazol-3-yl)-biphenyl-4-carboxylic acid methylamide;

1-[4-(4-{5-Methyl-3-[4'-(morpholine-4-carbonyl)-biphenyl-3-yl]-isoxazol-4-yl}-thiazol-2-yl)-piperidin-1-yl]-2-thiophen-2-yl-ethanone;

1-[4-(4-{5-Methyl-3-[3'-(morpholine-4-carbonyl)-biphenyl-3-yl]-isoxazol-4-yl}-thiazol-2-yl)-piperidin-1-yl]-2-thiophen-2-yl-ethanone;

1-(4-{4-[3-(4'-Amino-biphenyl-3-yl)-5-methyl-isoxazol-4-yl]-thiazol-2-yl}-piperidin-1-yl)-2-thiophen-2-yl-ethanone;

 $N-[3'-(5-Methyl-4-\{2-[1-(2-thiophen-2-yl-acetyl)-piperidin-4-yl]-thiazol-4-yl\}-isoxazol-3-yl)-biphenyl-4-yl]-methanesulfonamide;$ 

1-(4-{4-[3-(4'-Methanesulfonyl-biphenyl-3-yl)-5-methyl-isoxazol-4-yl]-thiazol-2-yl}-piperidin-1-yl)-2-thiophen-2-yl-ethanone;

2,2,2-Trifluoro-N-[3'-(5-methyl-4-{2-[1-(2-thiophen-2-yl-acetyl)-piperidin-4-yl]-thiazol-4-yl}-isoxazol-3-yl)-biphenyl-3-yl]-acetamide;

1-(4-{4-[3-(3'-Methanesulfonyl-biphenyl-3-yl)-5-methyl-isoxazol-4-yl]-thiazol-2-yl}-piperidin-1-yl)-2-thiophen-2-yl-ethanone;

 $3'-(5-Methyl-4-\{2-[1-(2-thiophen-2-yl-acetyl)-piperidin-4-yl]-thiazol-4-yl\}-isoxazol-3-yl)-biphenyl-4-carbonitrile;$ 

 $1-\{4-[4-(3-\{3-[3-(1,1-Dioxo-1\lambda6-thiomorpholin-4-yl)-prop-1-ynyl]-phenyl\}-5-methyl-isoxazol-4-yl\}-thiazol-2-yl]-piperidin-1-yl\}-2-thiophen-2-yl-ethanone;$ 

l-[4-(4-{5-Methyl-3-[4'-(1H-tetrazol-5-yl)-biphenyl-3-yl]-isoxazol-4-yl}-thiazol-2-yl)-piperidin-1-yl]-2-thiophen-2-yl-ethanone; and

1-[4-(4-{3-[4'-(4,5-Dihydro-1H-imidazol-2-yl)-biphenyl-3-yl]-5-methyl-isoxazol-4-yl}-thiazol-2-yl)-piperidin-1-yl]-2-thiophen-2-yl-ethanone;

or pharmaceutically acceptable salt thereof.

43. (Original) A composition comprising a compound of claim 1 and a pharmaceutically acceptable carrier.

Page 27 of 28

44. (Original) A method of modulating the follicle stimulating hormone (FSH) receptor comprising contacting said receptor with a compound of claim 1.

- 45. (Amended) A method of activating the follicle stimulating hormone (FSH) receptor comprising contacting said receptor with a compound of claim 1 or 42.
- 46. (Original) A method of increasing the adenylyl cyclase activity or the level of 5'-monophosphate (cAMP) in a cell, cell culture or tissue expressing the follicle stimulating hormone receptor comprising contacting said cell, cell culture or tissue with a compound of claim 1.
- 47. (Original) A method of inducing ovulation in a female mammal comprising administering to said female mammal an ovulation-inducing amount of a compound of claim 1.
- 48. (Amended) A method of treating a fertility disorder in a patient comprising administering to said patient a therapeutically effective amount of a compound of claim 1 or 42.
- 49. (Original) A method of treating infertility in a female patient comprising administering to said female patient a therapeutically effective amount of a compound of claim 1.